Immuron Ltd is a publicly listed Australian biopharmaceutical company (ASX: IMC) focused on oral immunotherapy using dairy-derived polyclonal antibody products for humans. Immuron is a uniquely positioned biotechnology company in view of its versatile technology platform, comprising dairy derived polyclonal antibodies, capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and raises the prospect that the clinical development of Immuron’s products will be expedited.
Immuron's recent media features:
Visit the ‘Well-travelled Travelan’ Facebook page